CY1111150T1 - Θεραπεια για υπερλιπαιμια - Google Patents

Θεραπεια για υπερλιπαιμια

Info

Publication number
CY1111150T1
CY1111150T1 CY20111100106T CY111100106T CY1111150T1 CY 1111150 T1 CY1111150 T1 CY 1111150T1 CY 20111100106 T CY20111100106 T CY 20111100106T CY 111100106 T CY111100106 T CY 111100106T CY 1111150 T1 CY1111150 T1 CY 1111150T1
Authority
CY
Cyprus
Prior art keywords
hyperployment
treatment
pitavastatin
ezetimibe
hyperlipemia
Prior art date
Application number
CY20111100106T
Other languages
English (en)
Inventor
Taro Aoki
Hiroyuki Yamazaki
Takashi Maejima
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35944235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111150(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Publication of CY1111150T1 publication Critical patent/CY1111150T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Παρέχεται θεραπευτικός παράγων για υπερλιπαιμία ή υπερχοληστερολαιμία, που περιλαμβάνει χορήγηση αποτελεσματικών δόσεων εζετιμίμπης και πιταβαστατίνης ή άλατος ή παραγώγου λακτόνης αυτής.
CY20111100106T 2004-08-31 2011-02-01 Θεραπεια για υπερλιπαιμια CY1111150T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60552504P 2004-08-31 2004-08-31
US10/997,878 US20060046996A1 (en) 2004-08-31 2004-11-29 Method for treating hyperlipidemia
EP05777087A EP1785137B1 (en) 2004-08-31 2005-08-30 Remedy for hyperlipemia

Publications (1)

Publication Number Publication Date
CY1111150T1 true CY1111150T1 (el) 2015-06-11

Family

ID=35944235

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100106T CY1111150T1 (el) 2004-08-31 2011-02-01 Θεραπεια για υπερλιπαιμια

Country Status (13)

Country Link
US (2) US20060046996A1 (el)
EP (1) EP1785137B1 (el)
JP (1) JP4886516B2 (el)
KR (1) KR101244508B1 (el)
CN (1) CN101010080B (el)
AT (1) ATE489093T1 (el)
CY (1) CY1111150T1 (el)
DE (1) DE602005024981D1 (el)
ES (1) ES2354366T3 (el)
HK (1) HK1110200A1 (el)
PL (1) PL1785137T3 (el)
PT (1) PT1785137E (el)
WO (1) WO2006025378A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
JP4719572B2 (ja) * 2003-04-17 2011-07-06 興和株式会社 Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
JP4688819B2 (ja) * 2003-12-23 2011-05-25 アストラゼネカ アクチボラグ コレステロール吸収阻害活性を有するジフェニルアゼチジノン誘導体
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011088055A2 (en) * 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
JPWO2020178878A1 (el) * 2019-03-01 2020-09-10
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185328A (en) 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5854259A (en) 1987-08-20 1998-12-29 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6465477B1 (en) 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CN101141964B (zh) * 2005-01-10 2013-06-05 科尔泰多投资公司 治疗糖尿病、代谢综合症和其它病症的组合物及方法

Also Published As

Publication number Publication date
ATE489093T1 (de) 2010-12-15
US7459447B2 (en) 2008-12-02
KR101244508B1 (ko) 2013-03-18
ES2354366T3 (es) 2011-03-14
KR20070047766A (ko) 2007-05-07
PT1785137E (pt) 2010-12-23
JP4886516B2 (ja) 2012-02-29
CN101010080A (zh) 2007-08-01
EP1785137B1 (en) 2010-11-24
PL1785137T3 (pl) 2011-04-29
US20070032467A1 (en) 2007-02-08
DE602005024981D1 (de) 2011-01-05
US20060046996A1 (en) 2006-03-02
CN101010080B (zh) 2011-02-09
EP1785137A1 (en) 2007-05-16
EP1785137A4 (en) 2007-12-19
HK1110200A1 (en) 2008-07-11
WO2006025378A1 (ja) 2006-03-09
JPWO2006025378A1 (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
CY1111150T1 (el) Θεραπεια για υπερλιπαιμια
CY2019030I1 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
CY1119381T1 (el) Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινης ως αναστολεις mtor
CY1116628T1 (el) Ενωσεις σπειρο-οξινδολιου και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1111721T1 (el) Ακυλαμινοπυραζολια ως αναστολεις fgfr
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
CY1108436T1 (el) Χορηγηση καψαϊκινοειδων
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
CY1110133T1 (el) Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ
ATE408601T1 (de) Fredericamycin-derivate
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
IS7076A (is) Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
MD3880197T2 (ro) Metode de tratament pentru fibroză chistică
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
ATE539078T1 (de) Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose
CY1108729T1 (el) 3,11b-cis-διυδpotetpabenazinh για την θεραπευτικη αντιμετωπιση μιας πολλαπλασιαστικης νοσου ή φλεγμονωδους παθησης
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων